Gil Morgan, MD
@weoncologists
Followers
16K
Following
39K
Media
2K
Statuses
27K
Clinical Oncologist from Texas🇺🇸Director of @OncoAlert 🚨 Proudly NIH, NCI & MDA trained. An ounce of prevention equals a pound of cure. Views are own🌏
San Antonio, TX
Joined May 2009
A pleasure to publish this at @CD_AACR w/some AMAZING @OncoAlert 🚨colleagues/friends SoMe has immense potential in ALL areas of medicine⚕️ ☑️raises awareness on trials ☑️promotes cancer prevention ☑️amplifies oncology info ☑️enables diverse viewpoints https://t.co/CoLlKTV25f
14
95
250
📌 New @JCO_ASCO analysis of 8 RCTs explores HER2 in mCRC (RAS/BRAF WT, pMMR/MSS): n=1604 (HER2-pos: 5% | HER2-mut: 2%) https://t.co/UcuqFZIfQy 🧬 HER2-pos = worse outcomes • mPFS: 9.8 vs 12.2 mo (HR 1.31) • mOS: 28.0 vs 34.9 mo (HR 1.37) ❌ No benefit from bev or anti-EGFRs
0
3
4
✨ ¡Emocionada de compartir micrófonos con @nataliagandur en el podcast de @OncoAlert! 💬 Hablamos de las últimas actualizaciones en #OncoGU con visión para 🌎 LATAM y todos los hispanohablantes🎧
Oncología Ahora y En Directo! El nuevo podcast de OncoAlert 🚨 en nuestro idioma! Con nuestras colegas Dra. Natalia Gandur (Argentina) y Dra. Reginia Barragán (México). En este primer episodio, las doctoras Barragán-Carrillo y Gandur nos cuentan qué esperar de este webcast
0
2
7
Two important randomized trials in #PancreaticCancer published: 1st PASS-01 in metastatic cancer comparing FOLFIRINOX to Gem/Abraxane (@JCO_ASCO) 2nd PREOPANC-2 in resectable/borderline resectable cancer comparing neoadjuvant FFX versus Gem/CRT (@TheLancetOncol) @OncoAlert ⬇️
1
6
18
Clinicopathologic features and contralateral breast cancer risk in BRCA1/2 pathogenic variant carriers: a multicenter registry study of Japanese women https://t.co/jbaLIkfdWo A large🇯🇵 Japanese study of 2,949 🧬BRCA1/2 #BreastCancer patients examined tumor characteristics and
0
3
8
Family History of Prostate, Breast, Ovarian, and/or Pancreatic Cancer and Associations with Grade Reclassification in a Large Prostate Cancer Active Surveillance Cohort https://t.co/Ks6L6KEGj8 In a prospective cohort of 1,421 prostate cancer patients on active surveillance,
0
5
8
Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial https://t.co/3UXWsmT7FD The 10-year follow-up of the CHAARTED trial confirms that adding docetaxel to
1
25
51
Every week a summary with more important news Register for more ⤵️ and follow us @OncoAlert
https://t.co/5GJE5BipY2
oncoalert.m-pages.com
The Latest in Oncology delivered weekly to your inbox, a simple click and you are set to go!
The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week Aug28-Sept4, 2025 REGISTER at https://t.co/yzt83gqQkF OR https://t.co/dq8GEzl9ps Discussing ✅Neoadjuvant Pembrolizumab + Accelerated MVAC in Rare #BladderCancer Subtypes: Phase 2 Trial Results ✅Cytokine
0
3
7
🎙️ We’re grateful to welcome @weoncologists! Founder & Executive Director of @OncoAlert, a global network of oncology experts amplifying trusted cancer information and promoting equity in education. 🚀 Episode coming soon hosted by @Ioanna_Nixon & @DrVilmaPBarcia. #Wellbeing
1
6
12
When @DrEdKim joined us at @cityofhope, he was charged with building out @cityofhopeoc - now practicing there myself, I can tell you it is a world-class institution! Hear highlights of his career journey here. Click below: https://t.co/sAOneN08ey
0
3
16
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3) Out on Lancet Oncology https://t.co/dI5m58ASr8 The long-term analysis of the PORTEC-3 trial evaluated adjuvant chemoradiotherapy versus radiotherapy alone in 660 women
0
18
49
Breast Cancer update! Current/future Tx strategies for pts w/ ER+/HER2- early breast cancer Expert insights from 19th St. Gallen Breast Cancer Conference Satellite Symposium Professor of Surgery Michael Gnant & Medical Oncologist Prof. Giuseppe Curigliano share their
1
11
64
Hi everyone, it's #WCLC25 Day 4 🎉🎉🎉 Check out the top influencers, most active posters and highest impressions! 🔥 @GlopesMd
@StephenVLiu
@CParkMD
@AndresFCardonaZ
@DrJNaidoo
@oncologician
@Tony_Calles
@HHorinouchi
@lungoncdoc
@UmbertoMalapel1
@NReguart
2
12
18
Oncología Ahora y En Directo! El nuevo podcast de OncoAlert 🚨 en nuestro idioma! Con nuestras colegas Dra. Natalia Gandur (Argentina) y Dra. Reginia Barragán (México). En este primer episodio, las doctoras Barragán-Carrillo y Gandur nos cuentan qué esperar de este webcast
0
4
6
Deep Learning Model for Breast Shear Wave Elastography to Improve Breast Cancer Diagnosis (INSPiRED 006) https://t.co/kxIESJZJaC This study evaluated the use of a deep learning model applied to shear wave elastography (AI-SWE) for improving the diagnosis of BI-RADS 3 and 4
0
11
20
JUST A FEW DAYS TO REGISTER for FREE A warm invite from @gotoPER 🚨to Join them In Person OR ONLINE (Streaming) at #ISGIO2025 Sept 12–13 REGISTER HERE👉 https://t.co/PdCaAuCrIt FREE HCP Registration (USE CODE: ONCOALERT )🚨 A unique multidisciplinary GI oncology meeting with
0
8
14
The @OncoAlert RoundUp is out! REGISTER at
The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week Aug28-Sept4, 2025 REGISTER at https://t.co/yzt83gqQkF OR https://t.co/dq8GEzl9ps Discussing ✅Neoadjuvant Pembrolizumab + Accelerated MVAC in Rare #BladderCancer Subtypes: Phase 2 Trial Results ✅Cytokine
0
5
11
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study https://t.co/tKwSQcQFd1 The phase III KEYNOTE-641 trial evaluated the combination
0
15
33
Association of patient and physician characteristics with androgen-deprivation-therapy intensification in patients with de novo hormone-sensitive metastatic prostate cancer: A population-based study https://t.co/DA0k0y1NSf Population-based study in Ontario 🇨🇦evaluated factors
1
14
27
💥 NADIM Adjuvant at #WCLC25! Stage IB–IIIA NSCLC, R0 resected, then: ChT+nivo (4C) → nivo (6C) vs. ChT alone (4C) At 36 months: 🎯DFS: 73.3% vs 59.9% (HR 0.65) 🎯Cancer-specific DFS (HR 0.55, p=0.029) The data blooms nicely…let’s see what full maturity brings 🌸 Congrats
1
26
58